Loading...
Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
PURPOSE: Mutations in the RET proto-oncogene and vascular endothelial growth factor receptor (VEGFR) activity are critical in the pathogenesis of medullary thyroid cancer (MTC). Sorafenib, a multikinase inhibitor targeting Ret and VEGFR, showed antitumor activity in preclinical studies of MTC. PATIE...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
American Society of Clinical Oncology
2010
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2881718/ https://ncbi.nlm.nih.gov/pubmed/20368568 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.25.0068 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|